VYEPTI Infusion Locator

Find an infusion service provider in your area.

The VYEPTI Infusion Locator is provided for informational purposes only. This database includes infusion service providers compiled by Lundbeck that are known to have experience with migraine. The results shown may not be inclusive of all providers who may have experience with migraine in your area. Lundbeck does not guarantee the accuracy or completeness of any information provided herein. Users should contact providers directly with all medication, insurance coverage, facility, and other site-specific inquiries.

No fees or other remuneration have been or will be exchanged for an infusion service provider's inclusion in this database. Lundbeck is not affiliated with, and inclusion in this list does not represent an endorsement of or referral to the providers contained in this database; nor does it represent an endorsement of any Lundbeck product by any provider listed. Users are responsible for compliance with state and federal laws regulating physician referrals, including state professional practice restrictions. Lundbeck and its affiliates hereby disclaim any liability arising from your use of and/or reliance on the information contained in this VYEPTI Infusion Locator.

If you are a provider whose practice is currently being shown on the VYEPTI Infusion Locator and you would like to opt out or update your information, please send us a request by clicking “Contact Us” at the bottom of this page. EPT-B-100298v4

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.